Lexeo Therapeutics, Inc.
LXEO
$7.50
-$0.18-2.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -32.99% | -11.11% | 9.08% | 123.70% | 35.82% |
| Gross Profit | 32.99% | 11.11% | -9.08% | -123.70% | -35.82% |
| SG&A Expenses | -26.69% | 128.43% | 120.35% | 33.29% | 168.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.37% | 30.31% | 45.14% | 82.86% | 55.59% |
| Operating Income | 31.37% | -30.31% | -45.14% | -82.86% | -55.59% |
| Income Before Tax | 31.22% | -22.91% | -50.61% | -82.73% | -46.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.22% | -22.91% | -50.61% | -82.73% | -46.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.22% | -22.91% | -50.61% | -82.73% | -46.65% |
| EBIT | 31.37% | -30.31% | -45.14% | -82.86% | -55.59% |
| EBITDA | 31.50% | -30.58% | -45.50% | -83.74% | -56.00% |
| EPS Basic | 62.71% | 6.90% | -27.27% | 9.18% | 92.78% |
| Normalized Basic EPS | 62.81% | -5.05% | -27.21% | 9.10% | 92.79% |
| EPS Diluted | 62.71% | 6.90% | -27.27% | 9.18% | 92.78% |
| Normalized Diluted EPS | 62.81% | -5.05% | -27.21% | 9.10% | 92.79% |
| Average Basic Shares Outstanding | 84.44% | 32.03% | 18.35% | 101.21% | 1,932.53% |
| Average Diluted Shares Outstanding | 84.44% | 32.03% | 18.35% | 101.21% | 1,932.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |